KR102407059B1 - 갑상선 베타-작용제의 사용 - Google Patents

갑상선 베타-작용제의 사용 Download PDF

Info

Publication number
KR102407059B1
KR102407059B1 KR1020187033713A KR20187033713A KR102407059B1 KR 102407059 B1 KR102407059 B1 KR 102407059B1 KR 1020187033713 A KR1020187033713 A KR 1020187033713A KR 20187033713 A KR20187033713 A KR 20187033713A KR 102407059 B1 KR102407059 B1 KR 102407059B1
Authority
KR
South Korea
Prior art keywords
group
alkyl
compound
optionally substituted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187033713A
Other languages
English (en)
Korean (ko)
Other versions
KR20190039027A (ko
Inventor
홍지안 지앙
브라이언 리안
로셸 핸리
미샤 디너만
마크 에리온
세르지 보이어
Original Assignee
바이킹 테라퓨틱스 인코포레이티드
메타베이시스 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이킹 테라퓨틱스 인코포레이티드, 메타베이시스 테라퓨틱스, 인크. filed Critical 바이킹 테라퓨틱스 인코포레이티드
Publication of KR20190039027A publication Critical patent/KR20190039027A/ko
Application granted granted Critical
Publication of KR102407059B1 publication Critical patent/KR102407059B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187033713A 2016-04-22 2017-04-24 갑상선 베타-작용제의 사용 Active KR102407059B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326436P 2016-04-22 2016-04-22
US62/326,436 2016-04-22
PCT/US2017/029120 WO2017185087A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (2)

Publication Number Publication Date
KR20190039027A KR20190039027A (ko) 2019-04-10
KR102407059B1 true KR102407059B1 (ko) 2022-06-10

Family

ID=60116400

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033713A Active KR102407059B1 (ko) 2016-04-22 2017-04-24 갑상선 베타-작용제의 사용

Country Status (10)

Country Link
US (3) US11351183B2 (enExample)
EP (1) EP3445373B1 (enExample)
JP (1) JP6931042B2 (enExample)
KR (1) KR102407059B1 (enExample)
AU (1) AU2017252126B2 (enExample)
BR (1) BR112018071586A2 (enExample)
CA (1) CA3021681C (enExample)
ES (1) ES2992773T3 (enExample)
MX (1) MX385085B (enExample)
WO (1) WO2017185087A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017252126B2 (en) 2016-04-22 2023-02-09 Metabasis Therapeutics, Inc. Use of thyroid beta-agonists
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
JP2025520449A (ja) * 2022-06-15 2025-07-03 バイキング セラピューティクス，インコーポレーテッド Ｘ－ａｌｄ治療のための甲状腺ベータ作動薬投与計画

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
CA2543132A1 (en) 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1930046A1 (en) 2004-12-08 2008-06-11 Sirion Therapeutics, Inc. Retinol binding protein and transthyretin modulators for treating diabetes
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
JPWO2007097289A1 (ja) 2006-02-20 2009-07-16 武田薬品工業株式会社 新規医薬
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
EP2723756B1 (en) 2011-06-21 2020-03-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
PE20180021A1 (es) 2015-02-20 2018-01-09 Univ Oregon Health & Science Derivados de sobetiroma
WO2017148801A1 (en) 2016-02-29 2017-09-08 Philip Morris Products S.A. Hinge-lid container and blank
AU2017252126B2 (en) 2016-04-22 2023-02-09 Metabasis Therapeutics, Inc. Use of thyroid beta-agonists
CN109641003A (zh) 2016-04-22 2019-04-16 维京治疗股份有限公司 甲状腺β-激动剂的应用
MX382313B (es) 2016-05-18 2025-03-13 Univ Oregon Health & Science Derivados del sobetiroma.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases

Also Published As

Publication number Publication date
BR112018071586A2 (pt) 2019-02-12
WO2017185087A1 (en) 2017-10-26
US11951114B2 (en) 2024-04-09
EP3445373A1 (en) 2019-02-27
JP2019515033A (ja) 2019-06-06
AU2017252126B2 (en) 2023-02-09
JP6931042B2 (ja) 2021-09-01
KR20190039027A (ko) 2019-04-10
US20250000880A1 (en) 2025-01-02
US20220257618A1 (en) 2022-08-18
MX2018012900A (es) 2019-07-01
MX385085B (es) 2025-03-14
EP3445373A4 (en) 2019-12-18
US11351183B2 (en) 2022-06-07
CA3021681C (en) 2024-09-24
US20190321379A1 (en) 2019-10-24
ES2992773T3 (en) 2024-12-18
CA3021681A1 (en) 2017-10-26
AU2017252126A1 (en) 2018-11-08
US12440502B2 (en) 2025-10-14
EP3445373B1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
US12440502B2 (en) Use of thyroid beta-agonists
AU2023202321B2 (en) Use of thyroid beta-agonists
KR20190125432A (ko) 글루타미나제 억제제를 사용하는 병용 요법
US11382908B2 (en) Compositions and methods for treating inflammatory bowel disease
CA3067746A1 (en) Compositions and methods for modulating hair growth
JP7019585B2 (ja) 核酸プロドラッグ
CA3083228A1 (en) Small molecule degraders that recruit dcaft15
HK40064933A (en) Use of thyroid beta-agonists
HK40013781A (en) Use of thyroid beta-agonists
HK40007271A (en) Use of thyroid beta-agonists
HK40013781B (en) Use of thyroid beta-agonists
WO2017127417A1 (en) Phosphopantothenate compounds
HK1257604A1 (en) Conjoint therapies with inhibitors of glucose production

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181121

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20190221

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20190318

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200423

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211111

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220318

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220603

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220607

End annual number: 3

Start annual number: 1

PG1601 Publication of registration